Edwards Lifesciences Corporation EW SPXR3KPHARMA
Company Overview
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Why Investors Should Care
Net profit has compounded at 10.1% per year over the last five years.
Maintains a net profit margin of 15.4%.
Carries low leverage with a debt-to-equity ratio of 0.07.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $6.07B (+11.5% YoY); net profit $1.07B.
- Trailing 12 Months Year-on-year growth — revenue +13.6%, earnings -25.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.8%, profit CAGR 10.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.80% |
| 1 Year: | 13.60% |
Compounded Profit Growth
| 5 Years: | 10.13% |
| 1 Year: | -25.40% |
Stock Price Performance
| 1 Year: | +15.73% |
| 6 Months: | +10.12% |
| 3 Months: | +4.58% |
| 1 Month: | +0.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.31 · Neutral
P/E of 53.51 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 10.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 53.5.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EW Edwards Lifesciences Corporation SPXR3KPHARMA | 89.90 | 53.51 | $51.76B | 0.00% | 10.64% | 9.18% | 9.80% | 10.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 883.50M | 841.80M | 821.50M | 888.50M | 894.80M | 943.70M | 906.60M | 977.70M | 993.00M | 1.09B | 1.09B | 1.17B | 1.13B | 925.00M | 1.14B | 1.19B | 1.22B | 1.38B | 1.31B | 1.34B | 1.37B | 1.32B | 1.22B | 1.28B | 1.24B | 1.27B | 1.33B | 1.37B | 1.35B | 1.39B | 1.41B | 1.53B | 1.55B | 1.65B | 1.74B |
| Gross Profit | 495.20M | 517.00M | 556.80M | 538.00M | 554.50M | 667.90M | 630.70M | 608.20M | 653.20M | 661.20M | 697.50M | 681.70M | 743.00M | 761.20M | 782.90M | 801.60M | 887.90M | 863.60M | 686.80M | 859.90M | 895.40M | 923.20M | 1.04B | 998.50M | 1.04B | 1.10B | 1.07B | 992.30M | 1.03B | 992.80M | 1.02B | 1.04B | 1.09B | 1.09B | 1.09B | 1.11B | 1.19B | 1.21B | 1.29B | 1.35B |
| Operating Income | - | - | - | - | - | 298.30M | 241.00M | 214.00M | - | 252.50M | 252.10M | 248.90M | - | 274.20M | 267.50M | 294.30M | - | 358.10M | -169.70M | 357.80M | - | 383.50M | 542.10M | 390.30M | 438.80M | 459.50M | 402.40M | 388.40M | 263.50M | 365.90M | - | 349.00M | 366.50M | 350.60M | - | 394.80M | 411.20M | 307.10M | 477.60M | 513.20M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 406.40M | 343.50M | 340.50M | 307.10M | 384.90M | 369.90M | 351.90M | 366.30M | 3.07B | 385.60M | 358.00M | 333.20M | 291.10M | 380.70M | 241.90M |
| Diluted EPS | 0.64 | 0.66 | 0.58 | 0.65 | 0.73 | 1.06 | 0.86 | 0.79 | -0.01 | 0.96 | 1.32 | 1.06 | 0.03 | 0.39 | 0.38 | 0.43 | 0.44 | 0.49 | -0.20 | 0.52 | 0.49 | 0.54 | 0.78 | 0.54 | 0.59 | 0.65 | 0.55 | 0.56 | 0.50 | 0.63 | 0.61 | 0.58 | 0.61 | 5.13 | 0.65 | 0.61 | 0.56 | 0.50 | 0.66 | 0.42 |
| R&D Expense | - | 101.80M | 112.50M | 113.00M | - | 128.70M | 134.40M | 142.90M | - | 143.20M | 154.10M | 161.80M | - | 171.40M | 191.90M | 195.50M | - | 187.40M | 182.10M | 195.50M | - | 207.00M | 225.30M | 238.00M | 228.60M | 250.80M | 233.60M | 261.20M | 243.70M | 242.80M | - | 256.70M | 271.80M | 253.40M | - | 254.60M | 276.20M | 280.70M | 263.30M | 278.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.32B | 1.45B | 1.68B | 1.90B | 2.05B | 2.32B | 2.49B | 2.96B | 3.44B | 3.72B | 4.35B | 4.39B | 5.23B | 4.46B | 5.01B | 5.44B | 6.07B |
| Gross Profit | 818.10M | 922.30M | 1.04B | 1.19B | 1.41B | 1.53B | 1.70B | 1.88B | 2.17B | 2.56B | 2.78B | 3.23B | 3.31B | 3.98B | 3.74B | 4.03B | 4.32B | 4.73B |
| Operating Income | - | - | - | - | - | - | - | - | 751.20M | 1.09B | 748.20M | 1.15B | 897.60M | 1.69B | 1.50B | 1.31B | 1.38B | 1.26B |
| Net Income | - | 229.10M | 218.00M | 236.70M | 291.50M | 389.10M | 811.10M | 494.90M | 569.50M | 583.60M | 722.20M | 1.05B | 823.40M | 1.50B | 1.52B | 1.40B | 4.17B | 1.07B |
| Diluted EPS | 1.10 | 1.95 | 1.83 | 1.98 | 2.46 | 1.71 | 3.74 | 2.25 | 2.61 | 2.70 | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 |
| R&D Expense | 139.20M | 175.50M | 204.40M | 246.30M | 291.30M | 323.00M | 346.50M | 382.90M | 442.20M | 552.60M | 622.20M | 752.70M | 760.70M | 903.10M | 843.60M | 962.90M | 1.05B | 1.08B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Mar 2011 | Jun 2011 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.62B | 1.77B | - | - | - | 1.98B | 2.22B | 2.71B | 3.52B | 4.06B | 4.51B | 5.67B | 5.32B | 6.49B | 7.24B | 8.50B | 8.29B | 9.36B | 13.06B | 13.70B |
| Total Equity | 835.00M | 878.80M | 1.16B | 1.31B | - | - | - | 1.33B | 1.47B | 1.54B | 2.19B | 2.50B | 2.62B | 2.96B | 3.14B | 4.15B | 4.57B | 5.84B | 5.81B | 6.65B | 10.00B | 10.34B |
| Cash & Equivalents | 141.80M | 218.70M | 334.10M | 396.10M | 325.20M | 175.60M | 244.00M | 171.20M | 310.90M | 420.40M | 653.80M | 718.40M | 930.10M | 818.30M | 714.10M | 1.18B | 1.18B | 862.80M | 769.00M | 1.13B | 3.05B | 2.94B |
| Long Term Debt | - | - | - | - | - | - | - | - | 189.30M | 593.10M | 598.10M | 596.90M | 822.30M | 438.40M | 593.80M | 594.40M | 595.00M | 595.70M | 596.30M | 597.00M | 597.70M | 598.30M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.66B | 2.67B | 2.49B | 2.64B | 2.99B | 3.36B |
| Current Liabilities | - | - | 290.50M | 337.80M | - | - | - | 335.20M | 347.40M | 345.60M | 426.10M | 476.20M | 532.50M | 1.42B | 876.60M | 902.40M | 893.90M | 1.03B | 1.02B | 1.20B | 1.51B | 1.81B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 153.20M | 165.30M | 251.40M | - | - | - | - | 549.70M | 704.40M | 1.00B | 926.70M | 1.18B | 1.05B | 1.73B | 1.22B | 895.80M | 542.30M | 1.60B |
| Investing Cash Flow | 58.80M | 40.10M | -61.50M | - | - | - | - | -316.10M | -211.70M | -647.20M | 76.70M | -595.80M | -531.10M | -1.72B | 252.30M | 173.80M | 2.31B | -712.90M |
| Financing Cash Flow | -134.10M | -91.80M | -103.90M | - | - | - | - | -158.60M | -268.50M | -473.20M | -1.10B | -115.60M | -486.90M | -356.30M | -1.58B | -711.00M | -983.00M | -956.80M |
| Capital Expenditure | -50.60M | -64.00M | -61.80M | -76.60M | -109.00M | -109.00M | -82.90M | -102.70M | -176.10M | -168.10M | -238.70M | -254.40M | -407.00M | -325.80M | -244.60M | -253.00M | -252.40M | -260.20M |
| Free Cash Flow | 102.60M | 101.30M | 189.60M | - | - | - | - | 447.00M | 528.30M | 832.60M | 688.00M | 928.50M | 647.30M | 1.41B | 973.60M | 642.80M | 289.90M | 1.33B |
| Share Buybacks | 306.50M | 95.50M | 200.00M | 303.40M | 344.10M | 496.90M | 300.90M | 280.10M | 662.30M | 763.30M | 795.50M | 263.30M | 625.40M | 512.80M | 1.73B | 879.60M | 1.16B | 893.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 66.1% | 69.8% | 71.8% | 70.8% | 74.2% | 74.7% | 73.1% | 75.2% | 73.1% | 74.5% | 74.8% | 74.4% | 75.4% | 76.1% | 83.8% | 80.5% | 79.5% | 78.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | 25.3% | 31.7% | 20.1% | 26.4% | 20.5% | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% |
| Net Margin % | - | 17.3% | 15.1% | 14.1% | 15.3% | 19.0% | 34.9% | 19.8% | 19.2% | 17.0% | 19.4% | 24.1% | 18.8% | 28.7% | 34.1% | 28.0% | 76.7% | 17.7% |
| ROE % | - | 19.8% | 16.7% | 17.8% | 19.9% | 25.2% | 37.0% | 19.8% | 21.7% | 19.7% | 23.0% | 25.2% | 18.0% | 25.8% | 26.2% | 21.1% | 41.8% | 10.4% |
| ROCE % | - | - | - | - | - | - | - | - | 18.9% | 25.7% | 16.8% | 20.5% | 14.2% | 22.6% | 20.6% | 16.0% | 11.9% | 10.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.21% | 58.79M | $5.30B |
| 2 | Vanguard Capital Management LLC | 6.53% | 37.62M | $3.39B |
| 3 | Vanguard Portfolio Management LLC | 4.59% | 26.41M | $2.38B |
| 4 | State Street Corporation | 4.57% | 26.32M | $2.37B |
| 5 | JPMORGAN CHASE & CO | 3.96% | 22.78M | $2.06B |
| 6 | Wellington Management Group, LLP | 2.92% | 16.83M | $1.52B |
| 7 | Geode Capital Management, LLC | 2.68% | 15.44M | $1.39B |
| 8 | Bank Of New York Mellon Corporation | 2.45% | 14.08M | $1.27B |
| 9 | Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 2.26% | 13.00M | $1.17B |
| 10 | Ninety One UK Ltd | 2.14% | 12.34M | $1.11B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EW
The New York Stock Exchange | NYSE - NYSE
<a href="https://news.google.com/rss/articles/CBMiP0FVX3lxTE93UWVlU3g1TVNpdTNEcjI2Yk9kSHU2Tnh5Y0stVFBGRWVkLW9wbU1EbHhQaHdIOE56d2V5NXVhSQ?oc=5" target="_blank">The New York Stock Exchange | NYSE</a> <font color="#6f6f6f">NYSE</fon…
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVFhiVTFSNzI3UldISFNBUVNHU09DaGFmYnZtR0hqbEtEQlp6YURvWXFZaDlqUG55T3FFNW43WGZwMjJPVXNDaUpzaUVicjRUSEM4ekYtbU9rdUg5bXJUVDloMjZNVVdReno5WGVUajBfcVJtSjZON3NqWmNoMk1YbTVPcjF3UzhKUHNhSE…
Edwards Lifesciences Corporation $EW Shares Acquired by Saudi Central Bank - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOUmxKX2JuRVN4UW5qTUI0TEc1UWpzZnE1WHI0VDRLcjNaMndQTlJXSmNwQ0w2NGFHWkNiWDZSTzdoendHSk1sNk1zRDk5UUc1dXdSNkM0UFhoVjVfUjFjMU1tRlhBZXd5eWhKdnBoMHVDSVJKRkhoejhiVmVLanlxMS1LaEtxamZBLWRNR2…
Edwards Lifesciences (EW) Stock Could Be 1% Above Fair Value On Cash Flow And Earnings - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQNm9IME52ZGFlZ2JHYXNVYnJWcUJWZDlORlZZbHE1WG9JdklSZ204MURLSUZxSWVzN0VPa3g5U2Z0NklHUlZNbHUydzY3NmVrZzJWc1d1bmMtZU9tZzl4ejlWaEFJM19nc0JLbXQ3aXFZWnExN1kzV2l1NFpYellycUhjQkZlbDRiQVliN0…
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock - Barchart.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNM0pKRDZvNTM5TngzMzR6SUdCNFh3TkZYcmw5QTNTcHZ5eGFKRGdQLXNqNy0tUW1IU3lZQ0wtZjNSU1VPcmNIVXBXQUVqUm9CMl9DTEpiNXNicTlEa0JUbmp6czM1TU9EckU2VUdaeEE2QnE5bXlUSElNYzdWZG5JWHFxM1g0Nm1KYkhBY3…
Edwards Lifesciences (EW) Stock Looks Above Fair Value As Its 22% Three Year Run Continues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWnhGUml0VGhxQ3gtY0FtbmxGZWRMRTJVWEJ6M1ZfV3hkbVpIemlnU3prWExWdmowVkExcGdZdGNMNHhMcE1pc1JwbFlSclV5OHR5R3lBb0p5TzlXWkloaHJjVEhMeG16bHcwX2NlYXdMQWZGNExQOHcxekp0ZmhGV25yLVBnb2VEYjdSMF…
EW — Frequently Asked Questions
What is the current share price of Edwards Lifesciences Corporation (EW)?
As of 2026-09-07 16:24 PDT, Edwards Lifesciences Corporation (EW) trades at $89.90 on NYSE. Its 52-week range is $72.65 to $95.18.
What is the market capitalisation of EW?
Edwards Lifesciences Corporation (EW) has a market capitalisation of $51.76B on NYSE.
What is the P/E ratio of EW?
EW trades at a trailing price-to-earnings (P/E) ratio of 53.51. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.01.
What is the return on equity (ROE) of EW?
EW has a return on equity (ROE) of 9.18%. Its return on capital employed (ROCE) is 10.64%.
Is EW a good stock to buy?
This page provides a data-driven analysis of Edwards Lifesciences Corporation (EW), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.